Cargando…
Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial
PURPOSE: Microbiological diagnosis (MD) of infections remains insufficient. The resulting empirical antimicrobial therapy leads to multidrug resistance and inappropriate treatments. We therefore evaluated the cost-effectiveness of direct molecular detection of pathogens in blood for patients with se...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633620/ https://www.ncbi.nlm.nih.gov/pubmed/28374097 http://dx.doi.org/10.1007/s00134-017-4766-4 |
_version_ | 1783269921951580160 |
---|---|
author | Cambau, Emmanuelle Durand-Zaleski, Isabelle Bretagne, Stéphane Brun-Buisson, Christian Cordonnier, Catherine Duval, Xavier Herwegh, Stéphanie Pottecher, Julien Courcol, René Bastuji-Garin, Sylvie |
author_facet | Cambau, Emmanuelle Durand-Zaleski, Isabelle Bretagne, Stéphane Brun-Buisson, Christian Cordonnier, Catherine Duval, Xavier Herwegh, Stéphanie Pottecher, Julien Courcol, René Bastuji-Garin, Sylvie |
author_sort | Cambau, Emmanuelle |
collection | PubMed |
description | PURPOSE: Microbiological diagnosis (MD) of infections remains insufficient. The resulting empirical antimicrobial therapy leads to multidrug resistance and inappropriate treatments. We therefore evaluated the cost-effectiveness of direct molecular detection of pathogens in blood for patients with severe sepsis (SES), febrile neutropenia (FN) and suspected infective endocarditis (SIE). METHODS: Patients were enrolled in a multicentre, open-label, cluster-randomised crossover trial conducted during two consecutive periods, randomly assigned as control period (CP; standard diagnostic workup) or intervention period (IP; additional testing with LightCycler(®)SeptiFast). Multilevel models used to account for clustering were stratified by clinical setting (SES, FN, SIE). RESULTS: A total of 1416 patients (907 SES, 440 FN, 69 SIE) were evaluated for the primary endpoint (rate of blood MD). For SES patients, the MD rate was higher during IP than during CP [42.6% (198/465) vs. 28.1% (125/442), odds ratio (OR) 1.89, 95% confidence interval (CI) 1.43–2.50; P < 0.001], with an absolute increase of 14.5% (95% CI 8.4–20.7). A trend towards an association was observed for SIE [35.4% (17/48) vs. 9.5% (2/21); OR 6.22 (0.98–39.6)], but not for FN [32.1% (70/218) vs. 30.2% (67/222), P = 0.66]. Overall, turn-around time was shorter during IP than during CP (22.9 vs. 49.5 h, P < 0.001) and hospital costs were similar (median, mean ± SD: IP €14,826, €18,118 ± 17,775; CP €17,828, €18,653 ± 15,966). Bootstrap analysis of the incremental cost-effectiveness ratio showed weak dominance of intervention in SES patients. CONCLUSION: Addition of molecular detection to standard care improves MD and thus efficiency of healthcare resource usage in patients with SES. ClinicalTrials.gov registration number: NCT00709358. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-017-4766-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5633620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-56336202017-10-23 Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial Cambau, Emmanuelle Durand-Zaleski, Isabelle Bretagne, Stéphane Brun-Buisson, Christian Cordonnier, Catherine Duval, Xavier Herwegh, Stéphanie Pottecher, Julien Courcol, René Bastuji-Garin, Sylvie Intensive Care Med Original PURPOSE: Microbiological diagnosis (MD) of infections remains insufficient. The resulting empirical antimicrobial therapy leads to multidrug resistance and inappropriate treatments. We therefore evaluated the cost-effectiveness of direct molecular detection of pathogens in blood for patients with severe sepsis (SES), febrile neutropenia (FN) and suspected infective endocarditis (SIE). METHODS: Patients were enrolled in a multicentre, open-label, cluster-randomised crossover trial conducted during two consecutive periods, randomly assigned as control period (CP; standard diagnostic workup) or intervention period (IP; additional testing with LightCycler(®)SeptiFast). Multilevel models used to account for clustering were stratified by clinical setting (SES, FN, SIE). RESULTS: A total of 1416 patients (907 SES, 440 FN, 69 SIE) were evaluated for the primary endpoint (rate of blood MD). For SES patients, the MD rate was higher during IP than during CP [42.6% (198/465) vs. 28.1% (125/442), odds ratio (OR) 1.89, 95% confidence interval (CI) 1.43–2.50; P < 0.001], with an absolute increase of 14.5% (95% CI 8.4–20.7). A trend towards an association was observed for SIE [35.4% (17/48) vs. 9.5% (2/21); OR 6.22 (0.98–39.6)], but not for FN [32.1% (70/218) vs. 30.2% (67/222), P = 0.66]. Overall, turn-around time was shorter during IP than during CP (22.9 vs. 49.5 h, P < 0.001) and hospital costs were similar (median, mean ± SD: IP €14,826, €18,118 ± 17,775; CP €17,828, €18,653 ± 15,966). Bootstrap analysis of the incremental cost-effectiveness ratio showed weak dominance of intervention in SES patients. CONCLUSION: Addition of molecular detection to standard care improves MD and thus efficiency of healthcare resource usage in patients with SES. ClinicalTrials.gov registration number: NCT00709358. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00134-017-4766-4) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-04-03 2017 /pmc/articles/PMC5633620/ /pubmed/28374097 http://dx.doi.org/10.1007/s00134-017-4766-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Cambau, Emmanuelle Durand-Zaleski, Isabelle Bretagne, Stéphane Brun-Buisson, Christian Cordonnier, Catherine Duval, Xavier Herwegh, Stéphanie Pottecher, Julien Courcol, René Bastuji-Garin, Sylvie Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial |
title | Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial |
title_full | Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial |
title_fullStr | Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial |
title_full_unstemmed | Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial |
title_short | Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial |
title_sort | performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the evamica open-label, cluster-randomised, interventional crossover trial |
topic | Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633620/ https://www.ncbi.nlm.nih.gov/pubmed/28374097 http://dx.doi.org/10.1007/s00134-017-4766-4 |
work_keys_str_mv | AT cambauemmanuelle performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial AT durandzaleskiisabelle performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial AT bretagnestephane performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial AT brunbuissonchristian performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial AT cordonniercatherine performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial AT duvalxavier performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial AT herweghstephanie performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial AT pottecherjulien performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial AT courcolrene performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial AT bastujigarinsylvie performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial AT performanceandeconomicevaluationofthemoleculardetectionofpathogensforpatientswithsevereinfectionstheevamicaopenlabelclusterrandomisedinterventionalcrossovertrial |